Scott Henry
Overview
Explore the profile of Scott Henry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeong J, Rastogi A, Kim T, Henry S, Hoffmaster C, Kim S, et al.
Nucleic Acid Ther
. 2024 Nov;
34(6):285-294.
PMID: 39585752
Here, we present the reproductive toxicology profile of ISIS 838707, a GalNAc-conjugated antisense oligonucleotide (ASO) targeting mouse Apolipoprotein C-III (ApoC-III) mRNA. ISIS 838707 was subcutaneously administered during the premating, mating,...
2.
Johansson K, Maouia A, Rebetz J, Marcoux G, Shannon O, Italiano Jr J, et al.
J Thromb Haemost
. 2024 Aug;
22(11):3266-3276.
PMID: 39155024
Background: CpG oligonucleotides (ODNs) are synthetic single-stranded DNA sequences that act as immunostimulants. They have been increasingly used to treat several cancers; however, thrombocytopenia is a potential recognized side effect...
3.
Diep J, Yu R, Viney N, Schneider E, Guo S, Henry S, et al.
Br J Clin Pharmacol
. 2022 Jul;
88(12):5389-5398.
PMID: 35869634
Aims: Transthyretin-mediated amyloidosis is a progressive and fatal disease caused by the build-up of misfolded transthyretin (TTR) protein. Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotide targeting TTR messenger...
4.
Wang Y, Diep J, Yu R, Hurh E, Karwatowska-Prokopczuk E, Schneider E, et al.
J Clin Pharmacol
. 2022 Jul;
63(1):21-28.
PMID: 35801818
The pharmacokinetics (PK) of 2'-O-methoxyethyl and phosphorothioate antisense oligonucleotides (ASOs), with or without N-acetyl galactosamine conjugation, have been well characterized following subcutaneous or intravenous drug administration. However, the effect of...
5.
Wang Y, Yu R, Henry S, Geary R
Expert Opin Drug Metab Toxicol
. 2019 May;
15(6):475-485.
PMID: 31144994
: Triantennary N-acetyl galactosamine (GalNAc) - conjugated antisense oligonucleotides (ASOs) have demonstrated improved hepatocyte uptake and pharmacologic activity over their parent unconjugated ASOs in animals and . : In this...
6.
Biliouris K, Gaitonde P, Yin W, Norris D, Wang Y, Henry S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2018 Jul;
7(9):581-592.
PMID: 30043511
A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that is the first approved treatment for spinal muscular atrophy (SMA). The model was built with data from...
7.
Capaldi D, Teasdale A, Henry S, Akhtar N, den Besten C, Gao-Sheridan S, et al.
Nucleic Acid Ther
. 2017 Nov;
27(6):309-322.
PMID: 29125795
This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider...
8.
Paz S, Hsiao J, Cauntay P, Soriano A, Bai L, Machemer T, et al.
Nucleic Acid Ther
. 2017 Jun;
27(5):272-284.
PMID: 28605247
Antisense oligonucleotides (ASOs) are widely accepted therapeutic agents that suppress RNA transcription. While the majority of ASOs are well tolerated in vivo, few sequences trigger inflammatory responses in absence of...
9.
Luu K, Norris D, Gunawan R, Henry S, Geary R, Wang Y
J Clin Pharmacol
. 2017 Apr;
57(8):1031-1041.
PMID: 28369979
Nusinersen is an antisense oligonucleotide intended for the treatment of spinal muscular atrophy. The pharmacokinetics of nusinersen, following intrathecal administrations, in the cerebrospinal fluid (CSF) and plasma of 72 pediatric...
10.
Luu K, Morgan E, Bhanot S, Geary R, Smith A, Bethune C, et al.
J Pharmacokinet Pharmacodyn
. 2017 Jan;
44(3):179-191.
PMID: 28132162
IONIS-GCGR (ISIS 449884) is an antisense oligonucleotide inhibitor of the glucagon receptor (GCGR). The objective of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of IONIS-GCGR via...